Bilal Hussain

Bilal Hussain

Auto-generated profile, based on publicly available information

Bilal Hussain

The Brooklyn Hospital Center, United States

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2022 in Radiology Case Reports
Verified
Journal Article
Open access
BHBilal Hussain
Bilal Hussain
DBDishang Bhavsar
Dishang Bhavsar
Vishal DhulipalaVishal Dhulipala
Vishal Dhulipala
Coronary artery intramural hematoma is a rare complication of percutaneous coronary intervention which develops from intimal tear of coronary artery and propagates by blood accumulation along the medial surface of adjacent segment. Fifty-three-year-old male presented with nonexertional chest pain; he was referred after a positive stress test with+ moderate lateral wall ischemia. Coronary angiography showed 80% lesion in mid-left anterior descending artery (mLAD). Angiogram after angioplasty with 2.0 mm × 15 mm balloon and 3.0 mm × 15 mm drug-eluting-stent demonstrated a new stenotic lesion distal to stented mLAD segment. Subsequently, an overlapping 3.0 mm × 30 mm stent was placed with effective restoration of blood flow through LAD. During percutaneous coronary intervention (PCI), balloon predilatation can result in plaque fracture and stent deployment may cause intimal tear forming intramural hematoma which can lead to post-PCI myocardial infarction necessitating prompt detection by intravascular imaging with intravascular ultrasound and optical coherence tomography. Management is based on individual patient's characteristics and includes medical therapy, angiographic surveillance or repeat PCI.

28 July 2024 in International Journal of Cardiology
Verified
Journal Article
Closed access
BHBilal Hussain
Bilal Hussain
CTConstantine Tarabanis
Constantine Tarabanis
MAMian Muhammad Salman Aslam
Mian Muhammad Salman Aslam
VDVishal Dhulipala
Vishal Dhulipala
PDPradeepkumar Devarakonda
Pradeepkumar Devarakonda
PMPedro Moreno
Pedro Moreno

5 April 2024 in Cardiovascular Revascularization Medicine
Verified
Journal Article
Closed access
BHBilal Hussain
Bilal Hussain
SDSanchit Duhan
Sanchit Duhan
AMAhmed Mahmood
Ahmed Mahmood
LALuay Al-Alawi
Luay Al-Alawi
MAMian Muhammad Salman Aslam
Mian Muhammad Salman Aslam
FWFahad Waqar
Fahad Waqar

19 May 2023 in Current Problems in Cardiology
Verified
Journal Article
Closed access
BHBilal Hussain
Bilal Hussain
SDSanchit Duhan
Sanchit Duhan
AMAhmed Mahmood
Ahmed Mahmood
LALuay Al-Alawi
Luay Al-Alawi
CVCarlos Vargas
Carlos Vargas
TAThomas Alexander
Thomas Alexander

30 September 2024 in American Journal of Preventive Cardiology
Verified
Journal Article
Open access
MKMubashar Karamat
Mubashar Karamat
BHBilal Hussain
Bilal Hussain
MAMunis Mahboob Ahmed
Munis Mahboob Ahmed
MHMohammad Hamza
Mohammad Hamza
JMJunaid Mir
Junaid Mir
BPBirjesh D Patel
Birjesh D Patel
Cancer induced chronic inflammation and cancer drugs effects on the vascular system can lead to rapidly progressing atherosclerotic burden. Statins drugs are known to reduce atherosclerotic plaque burden and inflammation. We studied outcomes of statins for anthracycline-related cardiac dysfunction (ARCD). We conducted an online systematic search on PubMed and Embase to identify studies assessing statins' role in alleviating ARCD. We selected 9 studies that had patients with ARCD and use of statins. We primarily focused on outcomes including incidence of heart failure (HF), mean changes in left ventricular ejection fraction (LVEF), end-diastolic volume (LVEDV), and end-systolic volume (LVESV) from baseline. Odds ratios (OR) were calculated using a random effect model in R-statistics. Among 9 studies with a total of 2784 patients we noticed a significant reduction in the incidence of HF among patients administered statins, with an OR of 0.52 (95 % CI 0.37-0.74, p < 0.0003), indicating a substantial protective effect. However, the mean changes in EF, LVEDV, and LVESV from baseline, represented by Hedges's g of 1.09 (95 % CI -0.40 to 2.57, p = 0.15), 0.91 (95 % CI -1.69 to 3.51, p = 0.47), and 1.32 (95 % CI -2.30 to 4.94, p = 0.49) respectively, were not statistically significant. (Figure 1). Our meta-analysis confirms statins' effectiveness in reducing risk of ARCD. However, their influence on EF, LVEDV, and LVESV remains uncertain, warranting further study.

18 July 2025 in Current Problems in Cardiology
Verified
Journal Article
Open access
BHBilal Hussain
Bilal Hussain
SDSanchit Duhan
Sanchit Duhan
BPBansari Patel
Bansari Patel
YCYu-Chun Chang
Yu-Chun Chang
MHMohammad Hamza
Mohammad Hamza
YSyasar sattar
yasar sattar
Tafamidis was FDA-approved for Transthyretin cardiomyopathy (ATTR-CM) due to its demonstrated reduction in mortality and hospitalizations. 976 studies from PubMed and Embase were screened. Seven studies were included that compared tafamidis treatment with no tafamidis for ATTR-CM. The mantel-Haenszel method was used for binary outcomes, and Hedges' g was used for continuous outcomes. Tafamidis was associated with decreased odds of mortality (OR 0.55, 95 % CI 0.42-0.73, I2=41 %, p<0.0001) and reduced CHF exacerbations (OR 0.71, 95 % CI 0.51-0.99, I2= 0 %, p= 0.04). While, CHF related hospitalizations (OR 0.35, 95 % CI 0.07-1.67, I2= 87 %, p= 0.19), atrial arrhythmias (OR 0.98, 95 % CI 0.67-1.42, I2= 0 %, p= 0.9), change in left ventricular ejection fraction (SMD 0.87, 95 % CI -0.37-2.11, I2=98 %, p= 0.17), left ventricular end-diastolic diameter from baseline (SMD -0.12, 95 % CI -0.41-0.18, I2= 0 %, p= 0.4), interventricular septal thickness from baseline (SMD -0.7, 95 % CI -1.57-0.17, I2= 96 %, p= 0.11) were not statistically different for tafamidis compared to no tafamidis for ATTR-CM. Tafamidis treatment in ATTR-CM is associated with reduced all-cause mortality and a lower incidence of CHF exacerbations. These observations are consistent with the ATTRACT trial, which supports the efficacy of tafamidis in treating ATTR-CM.